ArticleBrain & spine2026
Intrathecal pump therapy: a retrospective cohort with over 1500 pump-years of follow-up.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intrathecal therapy (ITT) is an established treatment for severe spasticity and chronic pain syndromes. However, long-term device-related complications, such as infections and surgical revisions, remain a significant clinical concern. Research question: This study aims to quantify the incidence of these complications in a large retrospective cohort and evaluate the impact of compounded intrathecal medications on device longevity. Methods: We conducted a retrospective cohort study of patients undergoing intrathecal pump implantation or replacement (2003-2025). Complication burdens were calculated and expressed as incidence per 100 pump-years. To evaluate temporal risk, Kaplan-Meier time-to-event analyses were performed for both infections and revisions. The impact of compounded therapy versus monotherapy on revision-free survival was compared using the Log-Rank test, and pump exchange intervals were analysed via the Mann-Whitney Results: The cohort included 132 patients (328 pumps), yielding a cumulative follow-up of 1551.6 pump-years. Nine infections occurred, corresponding to a low incidence of 0.58 per 100 pump-years. Forty-eight surgical revisions were performed, resulting in an incidence of 3.1 per 100 pump-years. The use of compounded medications was not associated with a statistically significant reduction in time to first or subsequent pump exchanges, and Log-Rank testing confirmed no significant difference in overall revision-free survival distributions between the monotherapy and compounding cohorts. Conclusion: With over 1500 cumulative pump-years of follow-up, ITT was associated with a low infection incidence and a moderate, time-dependent revision burden. The utilization of compounded intrathecal medications did not inherently compromise device survivability, providing empirical reassurance for individualized off-label therapy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.